1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP
  1. Terrapinzflyer
    Reckitt Benckiser raises profit forecast
    Maker of Nurofen and Cillit Bang finds legacy drug still dominating US heroin substitute market

    Reckitt Benckiser, the Anglo-Dutch household goods group behind Cillit Bang, Dettol and Nurofen, has raised its full-year profit growth forecast, suggesting that its legacy drugs business, which makes the prescription heroin substitute Suboxone, would finish the year much more strongly than previously anticipated.

    The little talked-about heroin substitute division of Reckitt is a legacy of Reckitt & Colman's chemical research in the 1970s and investors had previously been warned that sales and profits from this "non-strategic" operation were expected to drop steeply once exclusivity licences expire – as happened in the US this month.

    But today Reckitt pointed to the absence of any major copycat product in the US, suggesting this was likely to prolong Suboxone's market dominance at least until the end of the year. This unexpected piece of good fortune, combined with continued strong performance from leading brands such as Vanish, Calgon and Harpic, prompted the chief executive, Bart Becht, to increase his profit growth forecast by 20% to between 12% and 13%.

    Raised profit expectations for 2009 come after the high-margin heroin substitute unit posted a 42% increase in revenues to £394m, predominantly driven by growing sales in the US. The company has warned that "up to 80% of revenues and profits of [this] business might be lost to generic competition in 2010, with the possibility of further erosion thereafter."

    Becht was the highest-paid director of any FTSE-100 company last year, receiving a pay package of £36.8m in salary, bonuses, share incentive schemes and perks. His pay deals totalling more than £80m over the past three years.



    Simon Bowers
    guardian.co.uk, Tuesday 27 October 2009 16.25 GMT

    http://www.guardian.co.uk/business/2009/oct/27/reckitt-benckiser-raises-profit-forecast

Comments

  1. dyingtomorrow
    Good ... uh ... news?

    For some reason this makes me think of two things. One, a bunch of rich corporate executives in a penthouse toasting heroin, ("Gentlemen, to heroin!") and two, A Scanner Darkly. Heheh...
To make a comment simply sign up and become a member!